MHLW Alerts About Adverse Effects Of Antidepressants Including GSK’s Paxil
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare May 8 alerted physicians and patients on possible adverse effects of antidepressants. The drugs mentioned by the ministry include Paxil (paroxetine), Luvox/Depromel (fluvoxamine), Toledomin (milnacipran) and Zoloft (sertraline). The Ministry received 268 reports of aggressive behavior after taking the drugs, and actual damage occurred in 35 cases. A casual relation cannot be denied in four cases, according to MHLW. GlaxoSmithKline's Paxil accounts for half of selective serotonin reuptake inhibitors marketed in Japan, and since it was launched in 2000, roughly 1 million patients have taken the drug in Japan. The Japan Society of Mood Disorders has established a committee to raise public attention on the appropriate use of antidepressants. (Click here for more - Japanese languageYou may also be interested in...
Industry Delighted By ‘Fixed’ USMCA
Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.
NeuClone’s Trastuzumab Trial Succeeds
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports